$MTEM
Molecular Templates, Inc.

2016 Q2 Form 10-Q Financial Statement

#000156459016021828 Filed on August 01, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2015 Q2 2014 Q4
Revenue $1.530M $3.680M $3.680M
YoY Change -58.42% 0.0% 14.64%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin -$510.0K $2.480M $2.620M
YoY Change -120.56% 0.0% 6.94%
% of Gross Profit
Research & Development -$1.100M $10.14M $8.610M
YoY Change -110.85% 17.05% 0.94%
% of Gross Profit
Depreciation & Amortization $120.0K $260.0K $280.0K
YoY Change -53.85% -23.53% -33.33%
% of Gross Profit
Operating Expenses $5.908M $12.62M $11.23M
YoY Change -53.19% 13.28% 2.18%
Operating Profit -$8.941M
YoY Change
Interest Expense $40.00K $39.00K $20.00K
YoY Change 2.56% 30.0% -33.33%
% of Operating Profit
Other Income/Expense, Net -$996.0K $596.0K $1.560M
YoY Change -267.11% -91.06% 578.26%
Pretax Income $2.580M -$8.310M -$5.960M
YoY Change -131.05% 979.22% -20.64%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.864M -$8.306M -$5.964M
YoY Change -17.36% 984.33% -21.41%
Net Earnings / Revenue -448.63% -225.71% -162.07%
Basic Earnings Per Share -$0.10 -$0.12 -$0.09
Diluted Earnings Per Share -$0.10 -$0.12 -$0.12
COMMON SHARES
Basic Shares Outstanding 71.51M 71.33M
Diluted Shares Outstanding 72.82M

Balance Sheet

Concept 2016 Q2 2015 Q2 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $33.60M $67.00M $58.60M
YoY Change -49.85% 6.35% -10.81%
Cash & Equivalents $12.40M $10.57M $8.391M
Short-Term Investments $56.50M $50.20M
Other Short-Term Assets $1.300M $1.500M $800.0K
YoY Change -13.33% -46.43% -63.64%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $35.80M $72.20M $66.68M
YoY Change -50.42% 3.0% -22.47%
LONG-TERM ASSETS
Property, Plant & Equipment $200.0K $424.0K $557.0K
YoY Change -52.83% -39.43% -18.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Other Assets $200.0K $1.264M $1.159M
YoY Change -84.18% 5.33% 9.44%
Total Long-Term Assets $400.0K $1.654M $1.716M
YoY Change -75.82% -88.27% -90.52%
TOTAL ASSETS
Total Short-Term Assets $35.80M $72.20M $66.68M
Total Long-Term Assets $400.0K $1.654M $1.716M
Total Assets $36.20M $73.85M $68.40M
YoY Change -50.98% -12.29% -34.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.100M $635.0K $2.074M
YoY Change 388.19% -78.1% 22.79%
Accrued Expenses $2.700M $2.451M $3.180M
YoY Change 10.16% -74.73% 0.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.800M $25.53M $25.97M
YoY Change -77.28% -6.49% -3.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.600M $74.60M $66.40M
YoY Change -96.51% -12.34% -34.0%
Total Long-Term Liabilities $2.600M $74.60M $66.40M
YoY Change -96.51% -12.34% -34.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.800M $25.53M $25.97M
Total Long-Term Liabilities $2.600M $74.60M $66.40M
Total Liabilities $8.400M $100.2M $92.37M
YoY Change -91.61% -10.89% -27.6%
SHAREHOLDERS EQUITY
Retained Earnings -$392.7M -$373.3M
YoY Change 6.14%
Common Stock $366.4M $349.3M
YoY Change 6.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.80M -$26.30M -$23.98M
YoY Change
Total Liabilities & Shareholders Equity $36.20M $73.85M $68.40M
YoY Change -50.98% -12.29% -34.31%

Cashflow Statement

Concept 2016 Q2 2015 Q2 2014 Q4
OPERATING ACTIVITIES
Net Income -$6.864M -$8.306M -$5.964M
YoY Change -17.36% 984.33% -21.41%
Depreciation, Depletion And Amortization $120.0K $260.0K $280.0K
YoY Change -53.85% -23.53% -33.33%
Cash From Operating Activities -$4.370M -$15.87M -$10.13M
YoY Change -72.46% 46.81% 5.41%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K -$10.00K
YoY Change -86.67% -80.0%
Acquisitions
YoY Change
Other Investing Activities $5.560M $5.380M $6.880M
YoY Change 3.35% -49.48% -46.29%
Cash From Investing Activities $5.560M $5.370M $6.870M
YoY Change 3.54% -48.86% -46.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 410.0K
YoY Change -100.0% 241.67%
NET CHANGE
Cash From Operating Activities -4.370M -15.87M -10.13M
Cash From Investing Activities 5.560M 5.370M 6.870M
Cash From Financing Activities 0.000 0.000 410.0K
Net Change In Cash 1.190M -10.50M -2.850M
YoY Change -111.33% 3520.69% -186.89%
FREE CASH FLOW
Cash From Operating Activities -$4.370M -$15.87M -$10.13M
Capital Expenditures -$20.00K -$10.00K
Free Cash Flow -$15.85M -$10.12M
YoY Change 48.69% 5.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10141000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1892000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2480000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
5908000
CY2015Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
39000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-996000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
596000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-8306000
us-gaap Net Income Loss
NetIncomeLoss
-19460000
CY2016Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10021000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20821000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
72000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
26000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6860000
us-gaap Operating Expenses
OperatingExpenses
25917000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-6864000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8941000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14162000
CY2016Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
40000
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8309000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14690000
us-gaap Contracts Revenue
ContractsRevenue
7361000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4141000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Operating Income Loss
OperatingIncomeLoss
-18556000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19465000
us-gaap Net Income Loss
NetIncomeLoss
-14716000
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71511000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
305000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
503000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
51000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-14000
us-gaap Share Based Compensation
ShareBasedCompensation
1645000
us-gaap Share Based Compensation
ShareBasedCompensation
3316000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-626000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-974000
thld Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-970000
thld Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-3601000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1305000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
773000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2351000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1439000
thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
-4737000
thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
1722000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2653000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-729000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
44000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
74000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-7361000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14999000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19706000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
13454000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
39479000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
61000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
1997000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
31192000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
30907000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
17799000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6630000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28514000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
28514000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2813000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2178000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8391000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10569000
CY2015Q2 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-308000
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6864000
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8614000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14716000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-19460000
CY2015Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1481000
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
802000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1895000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1645000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3316000
CY2016Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9032136
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2945000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
341939
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11635197
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11527107
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7444072
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.77
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.53
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.07
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.97
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.99
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.61
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M26D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y3M15D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y8M12D
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
300142
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
292477
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
16920
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
CY2016Q2 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
33591000
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
48510000
CY2016Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
21184000
CY2016Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2016Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
21189000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
39112000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
22000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
thld Weighted Average Maturity For Available For Sale Securities
WeightedAverageMaturityForAvailableForSaleSecurities
P3M6D
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
5524000
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
388000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
260000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
648000
CY2015Q4 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
40
CY2015Q4 us-gaap Severance Costs1
SeveranceCosts1
2500000
CY2015Q4 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
200000

Files In Submission

Name View Source Status
0001564590-16-021828-index-headers.html Edgar Link pending
0001564590-16-021828-index.html Edgar Link pending
0001564590-16-021828.txt Edgar Link pending
0001564590-16-021828-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
thld-10q_20160630.htm Edgar Link pending
thld-20160630.xml Edgar Link completed
thld-20160630.xsd Edgar Link pending
thld-20160630_cal.xml Edgar Link unprocessable
thld-20160630_def.xml Edgar Link unprocessable
thld-20160630_lab.xml Edgar Link unprocessable
thld-20160630_pre.xml Edgar Link unprocessable
thld-ex311_9.htm Edgar Link pending
thld-ex312_7.htm Edgar Link pending
thld-ex321_8.htm Edgar Link pending
thld-ex322_11.htm Edgar Link pending